By Connor Hart
Weight-loss drug stocks slid after the Centers for Medicare & Medicaid Services said it wouldn't finalize a provision set to provide coverage for anti-obesity medications. The agency added it may address the provision--which would have expanded coverage to about 3.4 million Medicare beneficiaries who have obesity not combined with a condition for which these medications are already covered--in future rulemaking as appropriate. Shares of Eli Lilly fall 2.9%, to $717.02, in after-hours trading. American depository receipts of Novo Nordisk slide 1.4%, to $61.68, and shares of Hims & Hers edge 1.2% lower, to $25.68.
Maxeon Solar Technologies said it is establishing an alternative network of supply-chain partners and increasing its manufacturing capabilities in the U.S. as it deals with new tariffs and trade barriers. The solar-technology company added it is also identifying additional domestic component vendors to support its diversified manufacturing operations. Shares climb 3.2%, to $2.89, in post-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 04, 2025 18:23 ET (22:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.